( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Andrew F. Lukwaro, Akanganyira Kasenene and Prof. Xujun Ye


Background: Tuberous sclerosis or tuberous sclerosis complex (TSC) is a genetic disease caused by mutations in tuberous sclerosis complex 1(TSC1) or tuberous sclerosis complex 2 (TSC2) genes that affects multiple organs such as the kidneys, brain, lungs, heart, and skin. Objective: This systematic review aims to assess the clinical value of everolimus for various manifestations in TSC patients. Methods: We searched PubMed, Cochrane Library, Clinical Trials ( and Google Scholar from January 2009 to December 2018. We included RCTs published in English, enrolled patients aged 0-65 years, with a definitive diagnosis of TSC on everolimus therapy for at least 18 weeks, medically stable and unlikely to require surgery during the trial. Two reviewers singly extracted data, assessed study quality, and applicability, and the strength of evidence for each study graded by consensus. Results: Four RCTs that met inclusion criteria assessed the effects of everolimus in TSC patients, and two RCTs reported the impact of everolimus on rate of tumor response (angiomyolipoma, skin lesion, and subependymal giant cell astrocytomas), tumor volume, tumor progression rate. These two RCTs revealed a higher percentage of tumor response, a significant reduction in tumor size and low tumor progression rate when compared to placebo. And two studies described the impacts of everolimus on neurological manifestations of TSC wherein one showed reduced frequency of TSC-associated seizures and no improvement in neurocognitive functioning or behavior in the other. The most common everolimus-related adverse reactions were stomatitis and mouth ulceration. Conclusions: Everolimus produced a significant impact on the reduction of tumor size, angiomyolipoma progression rate, improved tumor response rate, reduced frequency of seizures, but no effects in neurocognitive functioning or behavior changes and, also everolimus increased the incidence of stomatitis and mouth ulcerations.

Keywords: Everolimus, Tuberous sclerosis, Tuberous sclerosis-associated manifestations, Randomized controlled trials.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.


    FEBRUARY 2024 issue has been successfully launched on 1 FEBRUARY 2024.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 February 2024 Issue has been Published, Kindly check it on

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia